Wading into parallel reviews as a reimbursement strategy

Share

The process of gaining reimbursement is one of the most expensive and perilous activities a medical technology company will undergo. Some are exploring how (and whether) a strategy that encourages working with both FDA and CMS at the same time can help cut down the resource costs associated with reimbursement.

Seth Goldenberg, director of product development strategy for NAMSA, gives advice on how parallel reviews fit in an overall reimbursement strategy, and offers some alternatives for medtech companies that might not be ready for a national decision. We dig into some success stories, some pitfalls, the wild west of local payor networking, and discuss how it all fits in the overarching value-based strategies being embraced by medtech today.

NOTE: Seth Goldenberg is a speaker for our upcoming DeviceTalks, Minnesota. Join us in June to further the discussion.

DeviceTalks West: Expertise you need to know

textadimage Medical device suppliers are light years away from the days when they merely filled orders to spec for medtech OEMs – as a visit to the upcoming DeviceTalks West will quickly confirm.

From incorporating steerability into catheters to getting validation and testing done right, the companies serving the medical device industry have become specialized experts in their own right.

Read on to discover five example of medical device expertise to be had at DeviceTalks West, which runs Dec. 11–12 in Orange County, Calif.

Speak Your Mind

*